Hornykiewicz Oleh
Center for Brain Research, Medical University of Vienna, Vienna, Austria.
Neurodegener Dis. 2008;5(3-4):114-7. doi: 10.1159/000113678. Epub 2008 Mar 6.
The article recapitulates some of the historical facts that led up to the recognition of dopamine (DA) as a biologically active substance in the brain and its crucial role in Parkinson's disease (PD). Three events to which the writer has been an eyewitness are specially highlighted and placed in their proper historical perspective: (1) the discovery of the striatal DA deficit in the PD brain; (2) the development of the DA replacement treatment with L-dopa, and (3) the 'birth' of the nigrostriatal DA pathway. The opposition to the new observations and their unexpected and far-reaching consequences will be illustrated by briefly discussing the strongly negative opinions expressed by some famous brain scientists of the day about the relationship between the substantia nigra, PD, and the DA-containing nigrostriatal fiber connection.
本文概述了一些历史事实,这些事实促成了多巴胺(DA)被确认为大脑中的一种生物活性物质及其在帕金森病(PD)中的关键作用。作者亲眼目睹的三个事件被特别强调,并置于适当的历史背景中:(1)在帕金森病大脑中发现纹状体多巴胺缺乏;(2)用左旋多巴进行多巴胺替代治疗的发展,以及(3)黑质纹状体多巴胺能通路的“诞生”。通过简要讨论当时一些著名脑科学家对黑质、帕金森病和含多巴胺的黑质纹状体纤维连接之间关系所表达的强烈负面意见,将说明对这些新观察结果的反对及其意想不到的深远后果。